Home/ Stocks/ GERN

Geron Corp

GERN XNAS

$1.39 -0.06 (-4.12%) ▼ 15-min delayed

Open

$1.50

High

$1.53

Low

$1.38

Volume

12.75M

Market Cap

$891.71M

About Geron Corp

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 258 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$51.84M	$-3,642,000	$-0.01
FY 2025	$183.88M	$-83,500,000	$-0.13
Q3 2025	$47.23M	$-18,428,000	$-0.03
Q2 2025	$49.04M	$-16,375,000	$-0.02

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for GERN yet. Check out our latest market news or earnings calendar.

Get GERN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Geron Corp.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.